EUVIMEDEUVIMED entdecken
Crossref

Quality Score Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Trends, Racial Disparities, and Impact on Outcomes

Diamantis I Tsilimigras, Selamawit Woldesenbet, Brittany L Waterman, Anne M Noonan, Timothy M Pawlik

Journal of the National Comprehensive Cancer Network · 2025-04 · 23 (4)

DOI: 10.6004/jnccn.2024.7089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2025-04. Verfasst von Diamantis I Tsilimigras und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Healthcare Disparities, Quality of Health Care. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Evaluation of the quality of care delivered to patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) has been limited. We sought to examine trends and racial/ethnic disparities in quality of care among patients with mPDAC as well as the impact on outcomes using a novel and easily applied quality metric.

Methods

Medicare beneficiaries diagnosed with mPDAC between 2005 and 2019 were identified using SEER-Medicare data. Achievement of a quality score based on 3 criteria was assessed: (1) cancer-specific survival (CSS) >12 months, (2) receipt of systemic therapy, and (3) utilization of hospice/palliative care services. We examined factors associated with achieving the quality score, including race/ethnicity, social vulnerability index (SVI), and year of treatment. The impact of the quality score on CSS was also analyzed.

Results

Among 14,147 patients with mPDAC, 62.2% (n=8,794) received systemic therapy, 83.3% (n=11,791) utilized palliative care/hospice services, and 13.7% (n=1,933) had CSS >12 months after diagnosis. Achievement of at least one quality criterion increased over time (from 84.5% in 2005 to 97.0% in 2019; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsHealthcare DisparitiesQuality of Health CareHumansFemaleAgedMaleUnited StatesSEER ProgramMedicareAged, 80 and overPalliative Care

Autor:innen und Institutionen

  • Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH.
  • Division of Palliative Care Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH.
  • Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH.

Zitieren

APA

Tsilimigras, D. I., Woldesenbet, S., Waterman, B. L., Noonan, A. M., & Pawlik, T. M. (2025). Quality Score Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Trends, Racial Disparities, and Impact on Outcomes. Journal of the National Comprehensive Cancer Network, 23(4). https://doi.org/10.6004/jnccn.2024.7089

Vancouver

Tsilimigras DI, Woldesenbet S, Waterman BL, Noonan AM, Pawlik TM. Quality Score Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Trends, Racial Disparities, and Impact on Outcomes. Journal of the National Comprehensive Cancer Network. 2025;23(4). doi:10.6004/jnccn.2024.7089

BibTeX
@article{Tsilimigras2025,
  author = {Tsilimigras, Diamantis I and Woldesenbet, Selamawit and Waterman, Brittany L and Noonan, Anne M and Pawlik, Timothy M},
  title = {Quality Score Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Trends, Racial Disparities, and Impact on Outcomes},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2025},
  volume = {23},
  number = {4},
  doi = {10.6004/jnccn.2024.7089}
}
Kostenlos starten →